Neuraltus Pharmaceuticals, Inc.
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 2004-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.neuraltus.com
Clinical Trials
4
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials
Safety and Efficacy Study of NP001 in Patients With Amyotrophic Lateral Sclerosis (ALS) and Systemic Inflammation
- First Posted Date
- 2016-06-09
- Last Posted Date
- 2018-05-07
- Lead Sponsor
- Neuraltus Pharmaceuticals, Inc.
- Target Recruit Count
- 138
- Registration Number
- NCT02794857
- Locations
- 🇺🇸
St. Joseph's Hospital and Medical Center - Barrow Neurology Clinics, Phoenix, Arizona, United States
🇺🇸Mayo Clinic Arizona, Scottsdale, Arizona, United States
🇺🇸Cedars-Sinai Medical Center, Los Angeles, California, United States
A Study of NP001 in Subjects With Amyotrophic Lateral Sclerosis (ALS)
- First Posted Date
- 2011-01-24
- Last Posted Date
- 2012-11-22
- Lead Sponsor
- Neuraltus Pharmaceuticals, Inc.
- Target Recruit Count
- 136
- Registration Number
- NCT01281631
- Locations
- 🇺🇸
Mayo Clinic, Scottsdale, Scottsdale, Arizona, United States
🇺🇸UC, Irvine, Irvine, California, United States
🇺🇸UCLA, Los Angeles, California, United States
Single-Ascending-Dose Safety/Tolerability of NP001 in Amyotrophic Lateral Sclerosis (ALS)
- First Posted Date
- 2010-03-23
- Last Posted Date
- 2010-10-06
- Lead Sponsor
- Neuraltus Pharmaceuticals, Inc.
- Target Recruit Count
- 56
- Registration Number
- NCT01091142
- Locations
- 🇺🇸
California Pacific Medical Center, San Francisco, California, United States
🇺🇸University of Kansas Medical Center - Landon Center on Aging, Kansas City, Kansas, United States
🇺🇸Department of Neurology; University of Kentucky Medical Center, Lexington, Kentucky, United States
Study of NP002 in Subjects With Idiopathic Parkinson's Disease to Treat Dyskinesias Due to Levodopa Therapy
- First Posted Date
- 2009-08-13
- Last Posted Date
- 2011-10-05
- Lead Sponsor
- Neuraltus Pharmaceuticals, Inc.
- Target Recruit Count
- 65
- Registration Number
- NCT00957918
- Locations
- 🇺🇸
Barrow Neurology Clinics at St. Joseph's Hospital and Medical Center, Phoenix, Arizona, United States
🇺🇸Keck/USC School of Medicine -Department of Neurology, Los Angelis, California, United States
🇺🇸Pacific Neuroscience Medical Group, Oxnard, California, United States